Zydus Lifesciences Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Thu Apr 09 2026

Zydus Lifesciences (NSE: ZYDUSLIFE) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With Zydus Lifesciences trading at Rs 1,050 — against a 52-week high of Rs 1,280 and a 1-year return of -10% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 5,400-5,800 Cr, with PAT expectations of Rs 950-1,050 Cr and margin projections of EBITDA 28-30%. This article covers the Zydus Lifesciences Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.

Table of Contents

Zydus Lifesciences Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Zydus Lifesciences has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar context:

Company	Date	Link
TCS	April 9, 2026	Preview on Univest
Infosys	April 23, 2026	Preview on Univest
Zydus Lifesciences	May 2026 (Expected)	This article

Why This Quarter Matters

Zydus Lifesciences enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. At a 1-year return of -10%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can begin a recovery.

Zydus Lifesciences Q4 FY26 Earnings Estimates

Zydus Lifesciences Q4 FY26 analyst estimates. Source MOFSL, YES Securities, JM Financial.

Access premium SEBI-registered research on Univest.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	Driver
Revenue	Rs 5,186 Cr	Rs 5,400-5,800 Cr	Volume + pricing
PAT	Rs 904 Cr	Rs 950-1,050 Cr	Operating leverage
Margin	EBITDA 28.8%	EBITDA 28-30%	Cost control
Key Growth	–	10-14% YoY revenue growth	Management execution
Dividend	—	Rs 8-12 per share	Board recommendation

Beyond headline numbers, investors will watch for FY27 guidance, margin trajectory, and order/deal pipeline updates. A positive surprise on any two of these parameters could drive a meaningful post-results re-rating.

Screen Zydus Lifesciences fundamentals on Univest Screener.

5 Key Factors That Will Drive Zydus Lifesciences Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 5,400-5,800 Cr in revenue for Q4 FY26 (Q3: Rs 5,186 Cr). Management’s ability to translate the order pipeline into recognised revenue will be the first test. Q4 is seasonally important for the Pharma sector, driven by year-end order execution and government capex push.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 28-30%, compared to EBITDA 28.8% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst given sector-wide cost pressure.

PAT Quality

Net profit is estimated at Rs 950-1,050 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean recurring profit print is more positively received than one inflated by non-operational gains.

Management Guidance for FY27

The most consequential output from the Q4 FY26 announcement will be FY27 guidance — revenue growth bands, margin targets, capex plans, and macro risk commentary. Credible and specific guidance for FY27 will be valued highly by institutional investors.

Dividend Declaration

Zydus Lifesciences is expected to consider a final dividend of Rs 8-12 per share at the board meeting. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.

5 Risks to Watch in Zydus Lifesciences Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty affecting all Indian equities. For Zydus Lifesciences, indirect impacts include FII outflows and earnings estimate cuts if global demand slows. Tariff negotiation progress between India and the US remains the key macro wildcard.

Earnings Miss Risk

If Zydus Lifesciences’s Q4 FY26 results miss estimates, the stock could correct sharply — regardless of the longer-term fundamental story. Investors should monitor revenue versus the Rs 5,400-5,800 Cr estimate and PAT versus Rs 950-1,050 Cr as the two primary watchpoints on results day.

FY27 Guidance Below Consensus

If management’s FY27 guidance for revenue or margins falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current macro environment, forward guidance carries more weight than the reported quarter.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in one week following the tariff announcement. Continued selling pressure would create headwinds for Zydus Lifesciences regardless of company-specific fundamentals.

Regulatory Risk

The Pharma sector operates within evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Zydus Lifesciences’s profitability beyond current consensus models.

Zydus Lifesciences Share Price and Analyst Ratings

Zydus Lifesciences share price snapshot and analyst ratings. Source: Brokerages, NSE data.

Zydus Lifesciences is trading at Rs 1,050 as of early April 2026, against a 52-week high of Rs 1,280 and 52-week low of Rs 880. Market cap stands at Rs 1,06,500 Cr. The 1-year return of -10% reflects sector headwinds alongside company-specific factors.

Brokerage	Rating	Target Price	Thesis
MOFSL	Buy	Rs 1,300	US complex generics; ZyCov-D
YES Securities	Buy	Rs 1,280	Sitagliptin + Asacol catalyst
JM Financial	Add	Rs 1,220	Consumer wellness + India
Bernstein	Outperform	Rs 1,260	Diversified pharma attractive

Download the Univest iOS App or Univest Android App to track Zydus Lifesciences’s live price and receive real-time Q4 result alerts.

Conclusion

Zydus Lifesciences Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma sector. Analysts project PAT of Rs 950-1,050 Cr and revenue of Rs 5,400-5,800 Cr. At a CMP of Rs 1,050 with analyst targets ranging from Rs 1,260 to Rs 1,300, the stock offers risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews across sectors, visit Univest Blogs.

Frequently Asked Questions

What is the Zydus Lifesciences Q4 results 2026 date?

The Zydus Lifesciences Q4 results 2026 date is May 2026 (Expected). The board of directors will meet to approve the audited Q4 FY26 financial results and consider a dividend recommendation for FY26.

What is the Zydus Lifesciences Q4 FY26 PAT estimate?

Analysts estimate Zydus Lifesciences Q4 FY26 PAT in the range of Rs 950-1,050 Cr, based on revenue of Rs 5,400-5,800 Cr and margin of EBITDA 28-30%. Actual results may differ from consensus estimates.

What is Zydus Lifesciences’s share price ahead of Q4 results?

Zydus Lifesciences is trading at Rs 1,050 as of early April 2026. The 52-week high is Rs 1,280 and the 52-week low is Rs 880. The 1-year return is -10% and market cap is Rs 1,06,500 Cr.

Will Zydus Lifesciences declare a dividend in Q4 FY26?

Zydus Lifesciences is expected to consider a final dividend of Rs 8-12 per share at the Q4 FY26 board meeting on May 2026 (Expected), subject to board approval and AGM ratification.

Which analysts have a Buy rating on Zydus Lifesciences?

MOFSL (Buy, Rs 1,300), YES Securities (Buy, Rs 1,280), JM Financial (Add, Rs 1,220), Bernstein (Outperform, Rs 1,260) have positive ratings on Zydus Lifesciences heading into Q4 FY26.

What were Zydus Lifesciences Q3 FY26 results?

Zydus Lifesciences reported Q3 FY26 revenue of Rs 5,186 Cr and PAT of Rs 904 Cr, with margin at EBITDA 28.8%. These form the baseline against which Q4 FY26 estimates are benchmarked.

When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.

Is Zydus Lifesciences a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. Zydus Lifesciences has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before making any investment decision. Use the Univest Screener to assess fundamentals independently.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.